Alliance for Pharmacy Compounding

Don't be misled by assertions that the API compounders use isn't tested or that there's no batch testing of sterile compounded preparations before dispensing ...

We’re seeking knowledgeable members for the following 2025 APC standing committees. If you have ideas you want to share and develop to enhance the future of compounding, here’s where you start. Committee terms run from Jan. 1 to Dec. 31, 2025, and all committee appointments must be approved by the APC Board of Directors. If you would like to be considered for appointment, click below, then fill out and submit the interest form by Nov. 30, 2024 at 5:00 pm EST. Submission of the interest form does not guarantee a committee appointment. https://ow.ly/MVny50UbhiS

???? ???? ????

APC's perspective continues to be well represented in news media, from major media outlets to smaller blogs and health-focused publications. Here’s a sampling from the past week or so: Inside Health Policy: https://ow.ly/n76e50Ubh0U Health: https://ow.ly/9Jez50Ubh0G Verywell Health: https://ow.ly/c1ww50Ubh0K Medical News Today: https://ow.ly/4aqa50Ubh0J CNN: https://ow.ly/kIGX50Ubh10 Pharmaceutical Executive Magazine: https://ow.ly/3oWG50Ubh0Q Specialty Pharmacy Continuum: https://ow.ly/MZzb50Ubh0I

Drugmakers are urging the FDA to prohibit compounded GLP-1s The FDA needs to hear from you and your patients NOW! Two years into the GLP-1 injectable shortage, drugmakers Eli Lilly and Novo Nordisk have asked the FDA to take emergency action to prohibit compounding of tirzepatide and semaglutide. Both companies sent letters to FDA asking that their API be added to the ‘demonstrably difficult to compound list.’ The fact is, millions of doses have been safely prepared and dispensed by compounding pharmacies across the U.S. during this shortage. GLP-1s are not particularly difficult for sterile compounding labs to prepare. APC is leading an effort to oppose the drugmakers’ request, and we need your help — whether your pharmacy compounds GLP-1 drugs or not. Take action today. Patient access to compounded drugs is at stake. https://lnkd.in/ec3QfSFg

As an alternative to individual membership, APC offers pharmacy/facility membership as an option for 503A pharmacies and 503B outsourcing facilities of any size. Join today: https://a4pc.org/pfm

No, said Kentucky’s attorney general, the state’s board of pharmacy cannot legally license pharmacists who live outside Kentucky. The BoP in May had proposed a rule that would have “require[d] any pharmacist working in another state and who provides services on a Kentucky citizen’s prescription to obtain a non-resident pharmacist license,” which would have made Kentucky the first state with such a requirement. https://ow.ly/4iwk50UamYq

The latest of APC’s new regional meetings — CompoundED UpDATE — is coming to the Phoenix area December 5. It’s an evening of learning, networking, and eating at the Staybridge Suites Scottsdale-Talking Stick. What you get: - Two hours of live CE on the benefits of low-dose naltrexone (learn the latest on dosing, safety, science and physiology) and restoring thyroid balance (including the most recent best practices on compounding with thyroid APls). - A briefing on current compounding issues, including GLP-1s - A great catered dinner - The chance to network with compounders in your area It’s all just $25 thanks to a generous grant from PCCA. If you’re in the area, you don’t want to miss it. Click here and register today! https://ow.ly/tKSm50U9wNz

Get the facts here about patient adverse events reporting and compounded GLP1s >>>

This (!)